Regeneron Pharmaceuticals, Inc. financial data

Symbol
REGN on Nasdaq
Location
777 Old Saw Mill River Road, Tarrytown, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 1, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 488 % -9.45%
Quick Ratio 84.3 % +10.8%
Debt-to-equity 27.9 % 0%
Return On Equity 15.1 % -7.24%
Return On Assets 11.8 % -7.3%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 114B USD +48.4%
Weighted Average Number of Shares Outstanding, Basic 105M shares -2.78%
Weighted Average Number of Shares Outstanding, Diluted 109M shares -5.89%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 14.2B USD +5.38%
Research and Development Expense 5.43B USD +15.6%
Costs and Expenses 10.4B USD +8.23%
Operating Income (Loss) 3.84B USD -1.64%
Nonoperating Income (Expense) 1.03B USD +51.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 4.87B USD +6.27%
Income Tax Expense (Benefit) 416M USD +56.8%
Net Income (Loss) Attributable to Parent 4.46B USD +3.17%
Earnings Per Share, Basic 41 USD/shares +3.62%
Earnings Per Share, Diluted 39 USD/shares +5.19%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2B USD +3.91%
Marketable Securities, Current 5.47B USD -30.6%
Accounts Receivable, after Allowance for Credit Loss, Current 5.61B USD -1.87%
Inventory, Net 3.21B USD +11.6%
Assets, Current 16.9B USD -11.6%
Deferred Income Tax Assets, Net 3.57B USD +24%
Operating Lease, Right-of-Use Asset 217M USD +179%
Intangible Assets, Net (Excluding Goodwill) 1.35B USD +22.6%
Other Assets, Noncurrent 1.54B USD +54.6%
Assets 38.2B USD +5.91%
Accounts Payable, Current 724M USD +28.9%
Employee-related Liabilities, Current 641M USD +3.67%
Contract with Customer, Liability, Current 482M USD -17.8%
Liabilities, Current 3.67B USD +4.52%
Contract with Customer, Liability, Noncurrent 206M USD +0.34%
Operating Lease, Liability, Noncurrent 204M USD +197%
Other Liabilities, Noncurrent 1.7B USD +16.3%
Liabilities 8.28B USD +5.07%
Accumulated Other Comprehensive Income (Loss), Net of Tax 52.5M USD
Retained Earnings (Accumulated Deficit) 33.7B USD +14.5%
Stockholders' Equity Attributable to Parent 29.9B USD +6.14%
Liabilities and Equity 38.2B USD +5.91%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 1.05B USD -30.9%
Net Cash Provided by (Used in) Financing Activities -1.09B USD -2413%
Net Cash Provided by (Used in) Investing Activities 648M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 604M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.02B USD +4.53%
Deferred Tax Assets, Gross 3.41B USD +29.8%
Operating Lease, Liability 234M USD +167%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 4.58B USD +2.96%
Lessee, Operating Lease, Liability, to be Paid 291M USD +182%
Operating Lease, Liability, Current 30.3M USD +59.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 44.8M USD +123%
Lessee, Operating Lease, Liability, to be Paid, Year One 43.1M USD +78.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 56.5M USD +262%
Lessee, Operating Lease, Liability, to be Paid, Year Three 42.6M USD +173%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30M shares 0%
Unrecognized Tax Benefits 1.31B USD +88.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 33.2M USD +168%
Additional Paid in Capital 13.5B USD +9.53%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 127M USD +11.2%
Interest Expense 71.1M USD +11.4%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%